Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31203480 | 0.82 | CA1 (0.52) | ALDH1A1SMN1; SMN2KMT2AMEN1DRD2 | |
| SCHEMBL4947001 | 0.80 | ALDH1A1 (0.43) | ALDH1A1GAADRD2TDP1CA12 | |
| SCHEMBL14494975 | 0.79 | ALDH1A1 (0.51) | ALDH1A1GAASMN1; SMN2HPGDKMT2A | |
| SCHEMBL4392250 | 0.79 | KMT2A (0.54) | ALDH1A1GAASMN1; SMN2HPGDKMT2A | |
| SCHEMBL30438953 | 0.77 | KMT2A (0.77) | SMN1; SMN2KMT2AMEN1TDP1 | |
| SCHEMBL4402193 | 0.77 | CYP17A1 (0.49) | QPCTGAASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4396662 | 0.76 | KMT2A (0.54) | ALDH1A1GAASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4403159 | 0.76 | TDP1 (0.43) | ALDH1A1GAAHPGDKMT2AMEN1 | |
| SCHEMBL1258720 | 0.75 | ALDH1A1 (0.53) | ALDH1A1GAASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL31300041 | 0.75 | ALDH1A1 (0.59) | ALDH1A1GAASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1300401-B1 | THIAZOLE DERIVATIVES FOR USE AS ANTIINFLAMMATORIES | DAINIPPON SUMITOMO PHARMA CO (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-7396842-B2 | Five-membered cyclic compounds | DIANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7396842-B2 | Five-membered cyclic compounds | DIANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| EP-1669070-A2 | 2-imino-thiazolidine and -oxazolidine derivatives for use as antiinflammatory agents | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-20050222226-A1 | Five-membered cyclic compounds | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2005-10-06 | — | — | US | disclosed |
| US-6919361-B2 | Five-membered-ring compound | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-07-19 | — | — | US | disclosed |
| US-20040072827-A1 | Five-membered-ring compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1300401-A1 | FIVE-MEMBERED-RING COMPOUND | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072827-A1 | Five-membered-ring compound | EPX, IL5, CCR9 | QPCT 1929/4885ALDH1A1 3257/4885GAA 4650/4885 |
| US-20050222226-A1 | Five-membered cyclic compounds | EPX, CCL11, CCR9 | QPCT 2058/4885ALDH1A1 3404/4885GAA 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.